3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Spinal Cord Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Muscular Atrophy
1
Medulloblastoma
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia
1
Familial ependymoma
1
Dendritic Cell Sarcoma, Interdigitating
1
Choroid Plexus Neoplasms
1
Child Nutrition Disorders
1
Central Nervous System Neoplasms
1
Cachexia
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Blast Crisis
1
Astrocytoma
1
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
pembrolizumab
75
Bevacizumab
75
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
Cyproheptadine
×
Clear all
NCT06175273
2025-09-18
POINT
University of Kentucky
Phase 2/3
Completed
19 enrolled